Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07763652 | A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07769502 | A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers | recruiting | Phase 2 | 168 | AbbVieINDUSTRY | 3 | Sep 22, 2026 |
| clinicaltrials |
| NCT07801508 | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07824349 | JUR-003 in Adult Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Juri Biosciences, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832617 | Protoacoustic Imaging For 3D Mapping | recruiting | — | 24 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833319 | Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer(PKUCH-R10) | recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833566 | Biopsy-site-marker in Breast Cancer | recruiting | — | 140 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835035 | Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy | recruiting | Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835087 | Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer | recruiting | N/A | 36 | Beijing Friendship HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835139 | Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction | recruiting | N/A | 534 | Fudan UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02620852 | Women Informed to Screen Depending on Measures of Risk (Wisdom Study)(WISDOM) | recruiting | N/A | 100,000 | University of California, San FranciscoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03237026 | Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients | recruiting | — | 360 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03909412 | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma(CarMob) | recruiting | Phase 1 | 18 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04084730 | Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | recruiting | Phase 2 | 280 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04503577 | Prospective Bladder Cancer Infrastructure (ProBCI)(ProBCI) | recruiting | — | 3,600 | Prospective Bladder Cancer Infrastructure FoundationOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04523428 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | recruiting | Phase 2 | 60 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | recruiting | Phase 2 | 96 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04935684 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation(TMF-Allo) | recruiting | Phase 2 | 150 | University Hospital, Clermont-FerrandOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05008848 | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | recruiting | Phase 3 | 600 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05259709 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | recruiting | Phase 1 | 50 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05274048 | Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | recruiting | Phase 1 | 18 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05296070 | Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | University of MiamiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05377047 | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer(TAORMINA) | recruiting | Phase 3 | 345 | Vastra Gotaland RegionOTHER_GOV | 6 | Sep 21, 2026 | clinicaltrials |
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T(VIOLET) | recruiting | Phase 1 / Phase 2 | 66 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05550415 | The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | recruiting | Phase 2 | 26 | Universitas IndonesiaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | recruiting | Phase 2 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer(INAVO122) | recruiting | Phase 3 | 230 | Hoffmann-La RocheINDUSTRY | 29 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06021626 | A Study of CRD3874-SI in People With Solid Tumors | recruiting | Phase 1 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma(ZANU-TAFA) | recruiting | Phase 1 / Phase 2 | 27 | Alvaro Alencar, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06038032 | ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial(RESILIENCE) | recruiting | N/A | 148 | University of AlbertaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06099119 | Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.(PERTseverance) | recruiting | Phase 4 | 100 | Hospital Clinico Universitario de SantiagoOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | recruiting | Phase 3 | 134 | Lai-ping ZhongOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors(ACESOT-1051) | recruiting | Phase 1 | 90 | Aprea TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06271291 | Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts | recruiting | — | 30,000 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06329869 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma(SG-ESCC) | recruiting | Phase 2 | 35 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06349590 | Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery(DIET) | recruiting | Phase 1 / Phase 2 | 80 | University of ChicagoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06375915 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy(PM-CARE) | recruiting | Phase 2 | 33 | Francesco De CobelliOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06411678 | Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer | recruiting | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06423950 | Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB) | recruiting | — | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06474182 | Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma(ProApix) | recruiting | N/A | 36 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06529822 | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | recruiting | Phase 1 | 64 | Washington University School of MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06549595 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT06603870 | Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis(STREAM-Line) | recruiting | Phase 4 | 330 | Ottawa Hospital Research InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06623266 | Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC | recruiting | N/A | 300 | Huashan HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06717750 | A Study of CSCJC3456 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 102 | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 22, 2026source: clinicaltrials